Circio Holding ASA Logo

Circio Holding ASA

CRNA | OL

Overview

Corporate Details

ISIN(s):
NO0012858564 (+5 more)
LEI:
5967007LIEEXZXFYNS31
Country:
Norway
Address:
Vollsveien 19, 1366 Lysaker
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Circio Holding ASA is a clinical-stage biotechnology company developing novel medicines based on its unique circular RNA (circRNA) expression platform. The company's primary focus is deploying its powerful circRNA vector technology to enhance next-generation gene and cell therapies for genetic and other difficult-to-treat diseases. Circio's proprietary platform is engineered for novel DNA, RNA, and viral therapeutics. The company also develops immunotherapies, including the TG01 cancer vaccine, with the strategic goal of becoming a leader in the field of circular RNA-based medicine.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Circio Holding ASA. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-05 10:29
Capital/Financing Update
Circio Holding ASA - Conversion of Convertible Bonds and funding requested unde…
English 4.0 KB
2025-08-28 07:00
Investor Presentation
Circio presents new circVec-AAV vectors showing up to 40x enhanced activity in …
English 2.9 MB
2025-08-28 07:00
Interim Report
Circio presents new circVec-AAV vectors showing up to 40x enhanced activity in …
English 836.4 KB
2025-08-28 07:00
Report Publication Announcement
Circio presents new circVec-AAV vectors showing up to 40x enhanced activity in …
English 7.3 KB
2025-08-21 07:00
Report Publication Announcement
Circio invites to first half 2025 report and R&D update webcast on 28 August
English 3.9 KB
2025-08-04 10:57
Capital/Financing Update
Circio Holding ASA Funding requested under additional financing commitment fr…
English 2.6 KB
2025-07-04 09:22
Share Issue/Capital Change
Circio Holding ASA: Registration of share capital increase following conversion…
Norwegian 2.5 KB
2025-06-30 21:49
Share Issue/Capital Change
Circio Holding ASA: Requested Conversion of Convertible Bonds
English 2.8 KB
2025-06-30 07:00
Regulatory News Service
NeoRegen Biotech and Circio advance circular RNA delivery collaboration into in…
English 6.1 KB
2025-06-20 11:01
Share Issue/Capital Change
Circio Holding ASA: Registration of share capital increase following conversion…
Norwegian 2.6 KB
2025-06-18 16:57
Major Shareholding Notification
Flaggemelding Star Kapital AS - Circio Holding ASA
Norwegian 853 bytes
2025-06-17 17:17
Capital/Financing Update
Circio Holding ASA - Funding requested under financing commitment from Atlas
English 2.8 KB
2025-06-17 13:48
Capital/Financing Update
Circio Holding ASA: Requested Conversion of Convertible Bonds
English 3.5 KB
2025-06-16 07:00
Environmental & Social Information
TG01 mutant RAS cancer vaccine data showing clinical benefit in multiple myelom…
English 593.2 KB
2025-06-16 07:00
Regulatory News Service
TG01 mutant RAS cancer vaccine data showing clinical benefit in multiple myelom…
English 7.2 KB

Automate Your Workflow. Get a real-time feed of all Circio Holding ASA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Circio Holding ASA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
1NKEMIA Logo
Offers contract R&D, develops tech platforms, and invests in life sciences ventures.
Spain IKM
2cureX AB Logo
Tests cancer drugs on patient-derived micro-tumors for personalized oncology treatments.
Sweden 2CUREX
4SC AG Logo
Developing epigenetic small-molecule drugs for cancers with high unmet medical needs.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using an OMV platform for major infectious diseases.
Sweden ABERA
ABIVAX Logo
Developing oral drugs for chronic inflammatory diseases like ulcerative colitis and Crohn's disease.
France ABVX
Abliva Logo
A clinical-stage biotech developing medicines for rare primary mitochondrial diseases.
Sweden ABLI
Achiko AG Logo
A liquidated health tech firm that developed aptamer diagnostics and a COVID-19 passport app.
Switzerland ACHI
Acticor Biotech Logo
Biopharma developing first-in-class drugs for acute stroke and other thrombotic diseases.
France ALACT
Active Biotech Logo
Develops immunotherapies for cancer and inflammatory diseases with significant unmet needs.
Sweden ACTI
Addex Therapeutics Ltd Logo
Develops oral small molecule drugs, allosteric modulators, for neurological disorders.
Switzerland ADXN